Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
Ripoll JG, Tulledge-Scheitel SM, Stephenson AA, Ford S, Pike ML, Gorman EK, Hanson SN, Juskewitch JE, Miller AJ, Zaremba S, Ovrom EA, Razonable RR, Ganesh R, Hurt RT, Fischer EN, Derr AN, Eberle MR, Larsen JJ, Carney CM, Theel ES, Parikh SA, Kay NE, Joyner MJ, Senefeld JW. Ripoll JG, et al. Among authors: tulledge scheitel sm. mBio. 2024 May 8;15(5):e0040024. doi: 10.1128/mbio.00400-24. Epub 2024 Apr 11. mBio. 2024. PMID: 38602414 Free PMC article.
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville TA, Larsen JJ, Ganesh R, O'Horo JC. Razonable RR, et al. Among authors: tulledge scheitel sm. Open Forum Infect Dis. 2022 Oct 6;9(10):ofac411. doi: 10.1093/ofid/ofac411. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36213724 Free PMC article.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Razonable RR, O'Horo JC, Hanson SN, Arndt RF, Speicher LL, Seville TA, Hall ST, Pike ML, Heyliger A, Larsen JJ, Ganesh R, Tulledge-Scheitel SM. Razonable RR, et al. Among authors: tulledge scheitel sm. J Infect Dis. 2022 Nov 11;226(10):1683-1687. doi: 10.1093/infdis/jiac346. J Infect Dis. 2022. PMID: 36124696 Free PMC article.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Razonable RR, et al. Among authors: tulledge scheitel sm. Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23. Mayo Clin Proc. 2022. PMID: 36058578 Free PMC article.
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
O'Horo JC, Challener DW, Speicher L, Bosch W, Seville MT, Bierle DM, Ganesh R, Wilker CG, Arndt RF, Arndt LL, Tulledge-Scheitel SM, Hanson SN, Razonable RR. O'Horo JC, et al. Among authors: tulledge scheitel sm. Mayo Clin Proc. 2022 Feb;97(2):327-332. doi: 10.1016/j.mayocp.2021.12.002. Epub 2021 Dec 16. Mayo Clin Proc. 2022. PMID: 35120695 Free PMC article.
COVID-19 Care Clinic in a Medical Center: Lessons Learned.
Tulledge-Scheitel SM, Billings TA, Fischer KM, Homme JH, Miller JM, North F, Sanderson RL, Schroeder DR, Vaughan MA, Croghan IT. Tulledge-Scheitel SM, et al. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211056796. doi: 10.1177/21501327211056796. J Prim Care Community Health. 2021. PMID: 34872410 Free PMC article.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, Borgen MD, Hanson SN, Hedin MC, Lenehan P, Puranik A, Seville MT, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Ganesh R. Razonable RR, et al. Among authors: tulledge scheitel sm. EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30. EClinicalMedicine. 2021. PMID: 34485873 Free PMC article.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan PJ, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR. Ganesh R, et al. Among authors: tulledge scheitel sm. J Clin Invest. 2021 Oct 1;131(19):e151697. doi: 10.1172/JCI151697. J Clin Invest. 2021. PMID: 34411003 Free PMC article.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, Destro Borgen MJ, Hanson SN, Kennedy BD, Kottke BB, Larsen JJ, Ramar P, Rosedahl JK, Seville MT, Speicher LL, Tulledge-Scheitel SM, Wilker CG, Razonable RR. Ganesh R, et al. Among authors: tulledge scheitel sm. J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377. J Infect Dis. 2021. PMID: 34279629 Free PMC article.
38 results